Peer-reviewed veterinary case report
The Novel Arylamidine T-2307 DemonstratesandActivity against Candida auris.
- Journal:
- Antimicrobial agents and chemotherapy
- Year:
- 2020
- Authors:
- Wiederhold, Nathan P et al.
- Affiliation:
- University of Texas Health Science Center at San Antonio · United States
Abstract
Theandactivity of the arylamidine T-2307 againstwas evaluated. T-2307 demonstratedactivity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition). Treatment with T-2307 (3 mg/kg subcutaneous [SC] once daily) also significantly improved survival (70% at 21 days postinfection) and reduced kidney fungal burden (5.06 logCFU/g) compared to control (0% survival and 7.09 logCFU/g) (< 0.01).
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/31844006/